OakChart

Candel Therapeutics Inc

CADLHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 9:55 AM ET

9.45+0.10 (1.07%)
2026-11-11 15:55 CET
Market cap
715.45 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-88.53 USD m
Free cash flow, TTM
-57.32 USD m
EPS diluted, TTM
-1.41
P/E
-
Compare

Price

CADL against its 20, 50 and 200-day averages
2050200beatmiss
6.008.0010.0012.0014.004.1M8.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CADLclose 9.4520-day 8.5750-day 9.99200-day 8.399.45

32.5% under 14.00 on 27 Aug 2026. Last 15 sessions, 27.8% high to low

Profile

CADL
52-week range, 53% of the way up
4.3514.00

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

IndexRUT
Employees55
IPOJul 27, 2021
Beta-0.30
ATR, 14d0.63
Rel volume0.32
Short float21.34%
Insider own19.83%
Inst own61.41%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap723.11M
Enterprise Value571.07M
Income-88.53M
Sales0.00M
Book/sh1.66
Cash/sh2.63
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees55
IPOJul 27, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B5.70
P/C3.59
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio16.09
Current Ratio16.09
Debt/Eq0.39
LT Debt/Eq0.39
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.41
EPS next Y-1.11
EPS next Q-0.34
EPS this Y-88.63%
EPS next Y18.19%
EPS next 5Y-
EPS past 3/5Y-3.41% -3.52%
Sales past 3/5Y- -
EPS Y/Y TTM-108.75%
Sales Y/Y TTM-
EPS Q/Q-463.69%
Sales Q/Q-
EarningsAug 13 BMO
EPS/Sales Surpr.-118.58% -

Ownership

Insider Own19.83%
Insider Trans-2.05%
Inst Own61.41%
Inst Trans9.64%
ROA-56.37%
ROE-81.84%
ROIC-50.54%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2010.21%
SMA50-5.40%
SMA20012.62%
Trades-

Technical

Shs Outstand76.12M
Shs Float61.34M
Short Float21.34%
Short Ratio11.10
Short Interest13.09M
52W High14.00 -32.50%
52W Low4.35 117.24%
Volatility9.87% 7.48%
ATR (14)0.63
RSI (14)53.45
Beta-0.30
Rel Volume0.32
Avg Volume1.18M
Volume41,967

Performance

Perf Week4.42%
Perf Month1.94%
Perf Quarter-19.91%
Perf Half Y5.71%
Perf YTD67.26%
Perf Year88.25%
Perf 3Y946.52%
Perf 5Y-13.70%
Perf 10Y-
Recom1.00
Target Price22.11
Prev Close9.35
Price9.45
Change %1.07%

Analyst ratings

latest 10 of 15
DateActionAnalystRating changeTargetImplied
Oct 22, 2026InitiatedJJefferiesBuy$25+164.5%
Sep 21, 2026UpgradeBBofA SecuritiesNeutral → Buy$18+90.5%
Jul 13, 2026InitiatedSStifelBuy$22+132.8%
Apr 20, 2026InitiatedCCantor FitzgeraldOverweight
Oct 28, 2025InitiatedSStephensOverweight$15+58.7%
Sep 03, 2025DowngradeBBofA SecuritiesBuy → Neutral$7-25.9%
Jun 30, 2025ResumedHH.C. WainwrightBuy$23+143.4%
Feb 20, 2025InitiatedCCitigroupBuy$25+164.5%
Feb 19, 2025InitiatedCCanaccord GenuityBuy$20+111.6%
Feb 07, 2025InitiatedBBofA SecuritiesBuy$15+58.7%

Peers

Mkt cap
TickerCompanyMkt cap
REPLReplimune Group Inc2.18B
CGONCg Oncology Inc6.71B
GNLXGenelux Corp89.36M
ONCYOncolytics Biotech Inc47.15M
PGENPrecigen Inc1.63B
JANXJanux Therapeutics Inc746.13M
TLXTelix Pharmaceuticals Ltd ADR3.27B
IOVAIovance Biotherapeutics Inc3.74B
IMCRImmunocore Holdings plc ADR1.65B
ELTXElicio Therapeutics Inc45.57M

Insider trading

11 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Tak Paul PeterChief Executive OfficerSep 10 '26Option Exercise1.55125,000193,750393,566Sep 11 06:12 PM
Tak Paul PeterChief Executive OfficerSep 10 '26Sale11.50220,8662,539,893172,700Sep 11 06:12 PM
Tak Paul PeterChief Executive OfficerSep 11 '26Sale10.4659,379620,891113,321Sep 11 06:12 PM
PAUL PETER TAKDirectorSep 10 '26Proposed Sale12.17280,2453,410,582Sep 10 04:39 PM
Tyagarajan SeshuChief Technology OfficerAug 17 '26Sale12.007,00084,00076,865Aug 19 04:30 PM
SESHU TYAGARAJANOfficerAug 17 '26Proposed Sale11.727,00082,040Aug 17 04:37 PM
Barone FrancescaChief Scientific OfficerJun 29 '26Sale10.0623,447235,76977,362Jul 01 04:22 PM
Tyagarajan SeshuChief Technology OfficerJun 29 '26Sale10.027,00070,15183,865Jul 01 04:22 PM
SESHU P TYAGARAJANOfficerJun 29 '26Proposed Sale9.797,00068,530Jun 29 04:44 PM
FRANCESCA BARONEOfficerJun 29 '26Proposed Sale9.7923,447229,546Jun 29 04:41 PM
Manning Paul BDirectorFeb 23 '26Buy5.45550,4582,999,9962,763,527Feb 26 07:38 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
KOMPState Street SPDR S&P Kensho New Economies Composite ETFAUM: 2.46B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 206
  • Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio (GlobeNewswire) +8.83%
  • Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -11.16%
  • Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.62%
  • Candel Therapeutics Announces Late-Breaking Abstract Accepted for Poster Presentation at the SITC 2026 Annual Meeting, Featuring Aglatimagene Besadenovec Data in Localized Prostate Cancer (GlobeNewswire)
  • Candel Therapeutics to Present at November Investor Conferences (GlobeNewswire) +5.91%
  • Loading…
  • Candel Therapeutics Appoints Maria Ostrovsky as General Counsel (GlobeNewswire)
  • Candel Therapeutics to Present at the SITC 2026 Annual Meeting (GlobeNewswire)
  • Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI (GlobeNewswire)
  • CADL Slips Despite Encouraging Prostate Cancer Drug Data Retail Believes Stock Is Clearly A Buy And Hold (Stocktwits)
  • Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer (GlobeNewswire)
  • Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026 (GlobeNewswire)
  • Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors (GlobeNewswire) -6.90%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-0.520-0.238-0.5200.000.007
2026Q12026-05-14-0.140-0.296-0.1420.000.007
2025Q42026-03-12-0.540-0.244-0.5370.000.007
2025Q32025-11-13-0.210-0.185-0.2050.000.007
2025Q22025-08-14-0.090-0.164-0.0930.000.004
2025Q12025-05-130.130-0.3750.1350.000.003
2024Q42025-03-13-0.400-0.228-0.3960.000.004
2024Q32024-11-14-0.330--0.3330.00--
2024Q22024-08-13-0.740--0.7440.00--
2024Q12024-05-14-0.280--0.2820.00--
2023Q42024-03-28-0.380-0.160-0.383-0.001
2023Q32023-11-09-0.290-0.190-0.2920.000.001
2023Q22023-08-10-0.330-0.299-0.3320.000.002
2023Q12023-05-11-0.300-0.350-0.3040.000.001
2022Q42023-03-30-0.180-0.306-0.1760.030.014
2022Q32022-11-10-0.300-0.354-0.3010.030.023

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-1.910-2.011-1.2590.000.03
2022FY-0.650-0.695-0.6520.080.08
2023FY-1.310-1.090-1.3110.100.00
2024FY-1.740-1.369-1.7420.000.00
2025FY-0.720-0.422-0.7200.000.00
2026FY--1.358--0.00
2027FY--1.111--41.92
2028FY-0.117--183.81
2029FY-1.612--437.7
2030FY-3.926--766.65

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-137000.000.000.00
2026Q3S2026-07-107000.000.000.00
2026Q3S2026-05-186000.000.000.00
2026Q3S2026-05-155000.000.000.00
2026Q3S2026-05-144000.000.000.00
2026Q3S2026-04-174000.000.000.00
2026Q3S2026-03-163000.000.000.00
2026Q3S2026-03-122000.000.000.00
2026Q3S2025-11-202000.000.000.00
2026Q3S2025-11-131000.000.000.00
2026Q3S2025-08-201000.000.000.00
2026Q3S2025-08-191000.000.000.00
2026Q3S2025-08-181000.000.000.00
2026Q3S2025-08-171000.000.000.00

Estimate history

EPS, annual-0.283-0.607-1.259-0.652-1.311-1.742-0.721-1.4095
Period2019202020212022202320242025TTM
EPS, quarterly-0.744-0.333-0.3960.135-0.093-0.205-0.537-0.142-0.525
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0.1250.1250.1250.1250000
Period2019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual29.14829.14828.6929.04229.21446.93355.02176.118
Period2019202020212022202320242025MRQ
Shares, quarterly31.06432.12546.93349.24754.8954.89655.02173.25876.118
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.120.120.120.12
Cost of Goods Sold Incl. D&A0.680.840.991.200.990.23--
Gross Profit-0.68-0.84-0.99-1.20-0.86-0.11--
Selling, General and Administrative Excl. Other71.3147.4232.3837.1933.8625.6213.849.12
Research and Development48.4529.6518.3223.3119.8014.958.666.56
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-71.99-48.27-33.37-38.39-34.72-25.73-13.81-9.04
Interest Expense4.722.122.092.600.490.05--
Unusual Expense17.01-8.2020.80-0.97-16.3710.964.610.84
Net Income Before Taxes-88.53-38.18-55.18-37.94-18.79-36.12-17.68-8.24
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-88.53-38.18-55.18-37.94-18.79-36.12-17.68-8.24
Net Income From Continuing Operations-88.53-38.18-55.18-37.94-18.79-36.12-17.68-8.24
Net Income-88.53-38.18-55.18-37.94-18.79-36.12-17.68-8.24
EPS (Recurring)-1.03-0.83-1.28-1.33-1.05-0.99-0.50-0.26
EPS (Basic, Before Extraordinaries)-1.41-0.72-1.74-1.31-0.65-1.26-0.61-0.28
EPS (Diluted)-1.41-0.72-1.74-1.31-0.65-1.26-0.61-0.28
EBITDA-71.31-47.42-32.38-37.19-33.73-25.49-13.72-8.99
Non-Operating Income (Expense)5.184.001.092.080.050.610.731.64
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense6.763.825.313.092.312.961.410.40
Price To Sales Ratio----412.751,794.84--
Gross Margin-----689.60-85.60--
Operating Margin-----27,777.60-20,580.80-11,048.00-7,229.60
Net Margin-----15,035.20-28,899.20-14,144.00-6,592.00
Shares Outstanding76.1255.0246.9329.2129.0428.6929.1529.15
Market Capitalization715.45715.45386.0542.5151.72224.35228.66-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.170.150.160.200.240.240.240.24
Gross Profit-0.17-0.15-0.16-0.20-0.24-0.24-0.24-0.24
Selling, General and Administrative Excl. Other26.5716.1415.5913.0110.947.887.908.51
Research and Development19.639.6910.878.276.753.774.575.17
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-26.75-16.28-15.75-13.21-11.18-8.13-8.14-8.76
Interest Expense1.571.561.420.160.240.310.390.49
Unusual Expense12.28-7.6413.52-1.15-5.69-14.885.831.64
Net Income Before Taxes-38.91-8.86-29.50-11.27-4.807.38-14.07-10.65
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-38.91-8.86-29.50-11.27-4.807.38-14.07-10.65
Net Income From Continuing Operations-38.91-8.86-29.50-11.27-4.807.38-14.07-10.65
Net Income-38.91-8.86-29.50-11.27-4.807.38-14.07-10.65
EPS (Recurring)-0.41-0.23-0.36-0.22-0.17-0.06-0.28-0.30
EPS (Basic, Before Extraordinaries)-0.52-0.14-0.54-0.21-0.090.15-0.40-0.33
EPS (Diluted)-0.52-0.14-0.54-0.21-0.090.13-0.40-0.33
EBITDA-26.57-16.14-15.59-13.01-10.94-7.88-7.90-8.51
Non-Operating Income (Expense)1.691.341.190.950.930.930.290.24
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.861.451.291.161.050.311.241.18
Shares Outstanding76.1273.2655.0254.9054.8949.2546.9332.13
Market Capitalization715.45358.91310.18279.96269.82266.88386.05222.35

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments119.73102.6535.4170.0682.6435.0545.06
Short Term Receivables0.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets1.661.151.381.892.300.090.15
Total Current Assets121.39103.8036.8071.9484.9435.1545.21
Net Property, Plant & Equipment3.302.734.025.483.842.790.42
Total Investments and Advances0.420.270.270.270.420.270.27
Intangible Assets---0.000.00-0.00
Deferred Tax Assets0.440.280.500.83---
Other Assets0.090.060.120.000.000.080.00
Total Assets125.63107.1441.7078.5289.2038.2845.90
Short Term Debt Incl. Current Port. of LT Debt0.4510.469.410.460.000.460.00
Accounts Payable1.130.240.420.381.590.920.22
Other Current Liabilities7.4226.834.364.773.773.331.19
Total Current Liabilities9.0037.5314.185.625.364.711.41
Long Term Debt48.593.0113.3622.340.560.480.42
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities0.440.280.500.83---
Other Liabilities15.690.000.922.0319.157.593.05
Total Liabilities73.7140.8228.9630.8025.0712.784.88
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.0049.0649.06
Common Equity51.9266.3312.7447.7164.14-23.56-8.04
Total Shareholders Equity51.9266.3312.7447.7164.1425.5041.02
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity51.9266.3312.7447.7164.1425.5041.02
Total Liabilities & Stockholders Equity125.63107.1441.7078.5289.2038.2845.90
Book Value Per Share0.941.410.441.642.24-0.81-0.28
Tangible Book Value Per Share0.941.410.441.642.24-0.81-0.28
Full-Time Employees5538427665--
Price to Book Ratio5.64-18.281.850.993.503.63-
Return on Assets-32.81-74.14-63.12-22.41-56.67-42.00-
Return on Equity-64.58-139.56-125.50-33.61-80.60-53.16-
Return on Invested Capital-37.99-79.58-145.35-26.83-55.84-68.05-19.88
Quick Ratio13.492.772.5912.8115.847.4632.06
Current Ratio13.492.772.5912.8115.847.4632.06

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-88.53-38.18-55.18-37.94-18.79-36.12-17.68-8.24
Depreciation0.680.840.991.200.990.230.090.04
Other Funds (Non Cash)25.48-3.1726.823.02-13.6814.556.742.51
Funds from Operations-62.37-40.50-27.37-33.72-31.49-21.34-10.85-5.69
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital6.352.190.35-0.530.07-0.881.770.51
Cash from Operating Activities-56.02-38.31-27.02-34.24-31.42-22.22-9.07-5.18
Capital Expenditures-1.30-0.59-0.02-0.46-1.30-1.83-1.48-0.16
Net Assets From Acquisitions0.000.000.000.000.000.000.00-0.85
Sale of Fixed Assets and Businesses0.030.030.000.180.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.0039.93-34.74
Purchase of Investments0.000.000.000.000.000.00-0.01-39.11
Sale Or Maturity of Investments0.000.000.000.000.000.0039.944.37
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-1.27-0.56-0.02-0.28-1.30-1.8338.45-35.74
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock117.1119.89103.450.000.0671.800.0322.50
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock117.1119.89103.450.000.0671.800.0322.50
Proceedsfrom Stock Options117.0319.37101.760.000.0071.330.0022.50
Issuance or Reduction of Debt, Net41.2136.21-9.170.0019.910.000.46-0.52
Change in Long Term Debt41.2136.21-9.170.0019.910.000.000.00
Issuance of Long Term Debt47.9547.950.000.0019.910.000.000.00
Reduction of Long Term Debt-6.73-11.73-9.170.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.00-0.120.000.000.000.00
Other Financing Activities Uses0.000.000.00-0.120.000.000.000.00
Cash from Financing Activities158.3256.1094.28-0.1219.9771.800.4921.98
Net Change in Cash101.0317.2367.24-34.65-12.7447.7529.87-18.94
Free Cash Flow-57.32-38.90-27.04-34.70-32.72-24.05-10.55-5.34
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments201.56194.83119.7386.96100.6992.17
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets2.592.921.663.172.920.98
Total Current Assets204.16197.75121.3990.13103.6193.15
Net Property, Plant & Equipment3.483.643.303.112.052.43
Total Investments and Advances0.420.420.420.270.270.27
Deferred Tax Assets--0.44---
Other Assets0.100.110.090.090.040.06
Total Assets208.15201.92125.6393.60105.9795.91
Short Term Debt Incl. Current Port. of LT Debt0.460.450.454.667.309.75
Accounts Payable5.153.041.131.121.950.76
Other Current Liabilities7.073.567.425.155.469.56
Total Current Liabilities12.697.059.0010.9314.7120.07
Long Term Debt49.0648.8248.592.541.041.16
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--0.44---
Other Liabilities20.288.0215.690.000.000.00
Total Liabilities82.0263.8973.7113.4715.7621.23
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity126.13138.0351.9280.1290.2174.67
Total Shareholders Equity126.13138.0351.9280.1290.2174.67
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity126.13138.0351.9280.1290.2174.67
Total Liabilities & Stockholders Equity208.15201.92125.6393.60105.9795.91
Book Value Per Share1.661.880.941.461.641.52
Tangible Book Value Per Share1.661.880.941.461.641.52
Full-Time Employees--55---
Price to Book Ratio5.645.193.873.103.344.00
Return on Assets-56.37-36.55-32.81-39.54-33.42-62.27
Return on Equity-81.84-51.17-64.58-70.17-55.18-98.14
Return on Invested Capital-22.21-4.74-29.35-13.63-5.269.73
Quick Ratio16.0928.0513.498.257.044.64
Current Ratio16.0928.0513.498.257.044.64

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-38.91-8.86-29.50-11.27-4.807.38
Depreciation0.170.150.160.200.240.24
Other Funds (Non Cash)15.59-5.7515.170.48-4.40-14.41
Funds from Operations-23.15-14.47-14.16-10.59-8.96-6.79
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital5.97-3.573.600.360.07-1.82
Cash from Operating Activities-17.18-18.04-10.57-10.24-8.89-8.62
Capital Expenditures-0.07-0.68-0.41-0.14-0.03-0.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.030.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.07-0.68-0.41-0.12-0.03-0.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock23.9893.810.00-0.6919.940.63
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock23.9893.810.00-0.6919.940.63
Proceedsfrom Stock Options23.9593.790.00-0.7119.700.38
Issuance or Reduction of Debt, Net0.000.0043.71-2.50-2.50-2.50
Change in Long Term Debt0.000.0043.71-2.50-2.50-2.50
Issuance of Long Term Debt0.000.0047.950.000.000.00
Reduction of Long Term Debt0.000.00-4.23-2.50-2.50-2.50
Net Financing Active Other Cash Flow0.000.000.18-0.180.000.00
Other Financing Activities Uses0.000.000.18-0.180.000.00
Cash from Financing Activities23.9893.8143.90-3.3717.44-1.87
Net Change in Cash6.7375.1032.92-13.728.52-10.49
Free Cash Flow-17.25-18.71-10.98-10.38-8.92-8.62

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3021.34%13.1M61.3M1.14M
2026-10-1520.82%12.8M61.3M1.18M
2026-09-3021.19%13.0M61.3M1.27M
2026-09-1520.12%12.3M61.3M1.51M
2026-08-3120.27%12.3M60.5M1.61M
2026-08-1420.60%12.5M60.5M1.73M
2026-07-3121.85%12.7M57.9M1.94M
2026-07-1522.37%13.0M57.9M2.14M
2026-06-3027.85%16.1M57.9M2.05M
2026-06-1523.52%13.6M57.9M1.81M
2026-05-2924.46%14.2M57.9M1.73M
2026-05-1524.89%14.4M58.0M1.78M
2026-04-3024.94%14.7M58.9M1.44M
2026-04-1525.60%15.1M58.9M1.17M
2026-03-3127.05%14.8M54.8M1.12M
2026-03-1325.89%14.2M54.8M1.01M
2026-02-2731.63%13.0M41.1M995.70K
2026-02-1322.64%9.3M41.1M780.09K
2026-01-3022.79%9.4M41.1M792.09K
2026-01-1522.71%9.3M41.1M784.11K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call3.004.109.000.0020.5050.000.000.978-0.0920.001
call4.003.108.000.0014.4590.000.000.936-0.1500.002
call5.002.157.000.0011.2120.000.000.895-0.1700.003
call6.001.156.002.009.0444.000.000.851-0.1750.003
call7.000.604.900.007.0880.000.000.803-0.1710.004
call8.000.104.901.187.9053840.000.746-0.1610.005
call9.000.401.500.758.5147860.000.775-0.2090.005
call10.000.004.900.602.8402790.000.601-0.1340.006
call11.000.000.400.252.4071090.000.416-0.0740.006
call12.000.000.350.101.88584.000.000.267-0.0510.005
call13.000.004.900.902.2291030.000.239-0.0570.005
call14.000.004.900.872.5196.000.000.220-0.0620.004
call15.000.004.900.052.7771560.000.207-0.0660.004
call16.000.000.050.101.80856.000.000.048-0.0140.002
call17.000.004.900.001.9880.000.000.045-0.0160.001
call18.000.000.050.302.1091.000.000.043-0.0150.001
call19.000.004.900.002.2790.000.000.041-0.0170.001
put3.000.004.900.0021.0160.000.00-0.022-0.0920.001
put4.000.004.900.0014.4850.000.00-0.064-0.1490.002
put5.000.004.900.0011.2670.000.00-0.105-0.1690.003
put6.000.004.900.009.0900.000.00-0.149-0.1740.003
put7.000.004.900.007.4230.000.00-0.198-0.1700.004
put8.000.002.501.105.7425120.00-0.262-0.1460.005
put9.000.004.900.499.7361290.00-0.247-0.2100.005
put10.000.004.901.208.3031120.00-0.399-0.1330.006
put11.000.104.902.006.86820.000.00-0.689-0.0430.005
put12.000.504.900.005.5680.000.00-0.733-0.0500.005
put13.001.156.000.005.9360.000.00-0.761-0.0560.005
put14.002.006.500.005.4630.000.00-0.795-0.0550.004
put15.003.007.900.006.4300.000.00-0.809-0.0580.004
put16.004.008.900.006.6770.000.00-0.951-0.0130.002
put17.005.009.900.006.9240.000.00-0.955-0.0140.001
put18.006.0010.900.007.1770.000.00-0.957-0.0140.001
put19.007.0011.900.007.3860.000.00-0.959-0.0140.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-054Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-11-053Initial statement of beneficial ownership of securities2026-11-03SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-09-114Statement of changes in beneficial ownership of securities2026-09-10SEC
2026-09-10144Filing for proposed sale of securities under Rule 144.SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-103Initial statement of beneficial ownership of securities2026-09-08SEC
2026-09-108-KCurrent report2026-09-06SEC
2026-09-098-KCurrent report2026-09-09SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-17144Filing for proposed sale of securities under Rule 144.SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-07-27SCHEDULE 13GSEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-06SEC
2026-07-083Initial statement of beneficial ownership of securities2026-07-06SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-29SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-06-29144Filing for proposed sale of securities under Rule 144.SEC
2026-06-29144Filing for proposed sale of securities under Rule 144.SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-244Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-248-KCurrent report2026-06-23SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09003.16M2
2026-080084.00K1
2026-070000
2026-0600305.92K2
2026-050000
2026-040000
2026-030000
2026-023.00M100
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
FMR LLC15.12%
RTW INVESTMENTS, LP8.76%
BlackRock, Inc.6.78%
STATE STREET CORP4.84%
ACORN CAPITAL ADVISORS, LLC4.77%
Portolan Capital Management, LLC4.76%
Saturn V Capital Management LP4.51%
VANGUARD CAPITAL MANAGEMENT LLC3.68%
GEODE CAPITAL MANAGEMENT, LLC2.23%
MILLENNIUM MANAGEMENT LLC1.49%

Funds

Fund% owned
Select Biotechnology Portfolio6.36%
Fidelity Growth Company Fund2.99%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.76%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.69%
Strategic Advisers U.S. Total Stock Fund2.50%
iShares Russell 2000 ETF2.25%
Fidelity Small Cap Index Fund0.95%
VANGUARD EXTENDED MARKET INDEX FUND0.90%
Fidelity Growth Company K6 Fund0.86%
Fidelity Series Growth Company Fund0.79%

OakChart. CADL. Cached 15 minutes.